2,326
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Sanofi's recently active trials. Comparator arms are excluded.
- Dupilumab8 trials
- Frexalimab6 trials
- Lunsekimig5 trials
- Belumosudil5 trials
- rilzabrutinib4 trials
- Amlitelimab4 trials
Upcoming readouts
Next primary completion dates among Sanofi's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Aug 2026A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Grave…Phase 2
- Dec 2026RESULT: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Parti…Phase 2
- May 2027MOBILIZE: A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyel…Phase 3
- Jun 2027Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chron…Phase 3
- Jul 2027VITALIZE: A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenou…Phase 3
- Jul 2027Frexcite: Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administ…Phase 3
Top therapeutic areas
Conditions studied most often across Sanofi's recently active trials.
- Dermatitis Atopic5 trials
- Asthma4 trials
- Multiple Sclerosis3 trials
- Type 1 Diabetes Mellitus3 trials
- Chronic Rhinosinusitis With Nasal Polyps3 trials
- Crohn's Disease3 trials
Sanofi trials
The 50 most significant of Sanofi's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| OPALEStudy in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in FranceNCT06393946Dupilumab | — | Locked · track to reveal | OngoingActive, not recruiting | 150 est. | 31 Jul 2026 |
| ATLAS-PEDSFitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or BNCT03974113Fitusiran | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 32 est. | 15 Aug 2026 |
| A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' DiseaseNCT06984627Rilzabrutinib dose 1 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 30 est. | 25 Aug 2026 |
| Validation of Chlamydia Diagnostic Codes in TriNetX US EHR DataNCT07094373 | — | Not yet scored | OngoingRecruiting | 533,000 est. | 31 Aug 2026 |
| Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsNCT07646548Dupilumab coformulated with berahyaluronidase alfa | Phase 1 | Locked · track to reveal | OngoingRecruiting | 40 est. | 30 Sept 2026 |
| A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)NCT04848779Alglucosidase alfa GZ419829 | — | Not yet scored | OngoingActive, not recruiting | 16 est. | 28 Oct 2026 |
| LEAPVenglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy ExtensionNCT02843035venglustat (GZ402671) | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 12 est. | 30 Oct 2026 |
| CEREN-2A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsNCT06834360Itepekimab (SAR440340) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 216 est. | 6 Nov 2026 |
| Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)NCT07457580Teplizumab | — | Not yet scored | OngoingRecruiting | 60 est. | 30 Nov 2026 |
| RESULTA Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseNCT06500702frexalimab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 84 est. | 23 Dec 2026 |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid TumorsNCT05584670SAR445877 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 542 est. | 19 Jan 2027 |
| FABULINUSFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)NCT06111586Frexalimab | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 197 est. | 28 Apr 2027 |
| FREXALTEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisNCT06141473Frexalimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,655 est. | 6 May 2027 |
| A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 YearsNCT07536048Investigational Procedure | — | Not yet scored | OngoingActive, not recruiting | 100 est. | 14 May 2027 |
| MOBILIZEA Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkNCT06290128Riliprubart | Phase 3 | Locked · track to reveal | OngoingRecruiting | 140 est. | 17 May 2027 |
| A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular DegenerationNCT06660667SAR402663 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 66 est. | 18 May 2027 |
| Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)NCT05263206Dupilumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 284 est. | 2 Jun 2027 |
| AIRLYMPUSStudy of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319Lunsekimig | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 556 est. | 21 Jun 2027 |
| VITALIZEA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)NCT06290141riliprubart | Phase 3 | Locked · track to reveal | OngoingRecruiting | 160 est. | 9 Jul 2027 |
| FrexciteNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisNCT07325292Frexalimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 160 est. | 15 Jul 2027 |
| SPECIFI-CDA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.NCT06637631SAR441566 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 260 est. | 21 Jul 2027 |
| LIBRAThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseNCT06975865Rilzabrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 192 est. | 23 Jul 2027 |
| SPECIFI-UCA Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisNCT06867094SAR441566 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 204 est. | 29 Jul 2027 |
| BRIGHTENBrivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaNCT07170917Brivekimig | Phase 2 | Locked · track to reveal | OngoingRecruiting | 208 est. | 1 Aug 2027 |
| Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolNCT04643002Isatuximab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 258 est. | 13 Sept 2027 |
| CLAROSA Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaNCT07225569SAR445399 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 144 est. | 22 Sept 2027 |
| AQUAA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorNCT06241118Amlitelimab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 636 est. | 30 Sept 2027 |
| A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationNCT07215234SAR446597 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 104 est. | 13 Oct 2027 |
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis BronchiectasisNCT07547436SAR445399 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 70 est. | 29 Oct 2027 |
| LUNA 4Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line TreatmentNCT07007962rilzabrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 60 est. | 5 Nov 2027 |
| Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of KoreaNCT07621653Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine | — | Not yet scored | OngoingNot yet recruiting | 706 est. | 23 Nov 2027 |
| SAR447971 First-in-human StudyNCT07629336SAR447971 | Phase 1 | Not yet scored | OngoingRecruiting | 114 est. | 16 Feb 2028 |
| KIBOU-T1DEfficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesNCT06791291Teplizumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 10 est. | 6 Mar 2028 |
| Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaNCT07710872MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA) | Phase 3 | Not yet scored | OngoingNot yet recruiting | 4,568 est. | 13 Mar 2028 |
| AD-BEASCUITSA Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab TreatmentNCT06192563Dupilumab | — | Locked · track to reveal | OngoingRecruiting | 150 est. | 31 Mar 2028 |
| A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With EmicizumabNCT06145373Fitusiran (SAR439774) | Phase 4 | Locked · track to reveal | OngoingRecruiting | 20 est. | 28 May 2028 |
| LUMINA 3A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic AnemiaNCT07086976rilzabrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 90 est. | 31 May 2028 |
| βETA PRESERVEA Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesNCT07088068Teplizumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 723 est. | 6 Jun 2028 |
| RILIEFA 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related DiseaseNCT07190196Rilzabrutinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 124 est. | 28 Jun 2028 |
| A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction CancerNCT07692204SAR445877 | Phase 2 | Not yet scored | OngoingRecruiting | 30 est. | 2 Aug 2028 |
| SUNSCAPE-2A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative ColitisNCT07185009Duvakitug | Phase 3 | Locked · track to reveal | OngoingRecruiting | 671 est. | 21 Sept 2028 |
| schoolROCKA Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)NCT07116031Belumosudil | Phase 2 | Locked · track to reveal | OngoingRecruiting | 37 est. | 25 Sept 2028 |
| OPALSPhase 1b/2 Study of IV Sarilumab in Adult With RANCT07704580Sarilumab, SAR153191 SC | Phase 1 | Not yet scored | OngoingRecruiting | 140 est. | 26 Oct 2028 |
| CEREN-3An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsNCT07424144Itepekimab (SAR440340) | Phase 3 | Locked · track to reveal | OngoingEnrolling by invitation | 380 est. | 12 Dec 2028 |
| AEOLUSA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.NCT07053423Dupilumab | Phase 4 | Locked · track to reveal | OngoingRecruiting | 218 est. | 23 Dec 2028 |
| RIVER-ADLong-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsNCT05492578Amlitelimab | Phase 2 | Locked · track to reveal | OngoingEnrolling by invitation | 1,663 est. | 22 Jan 2029 |
| ROCKaspireA Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft DysfunctionNCT06082037Belumosudil | Phase 3 | Locked · track to reveal | OngoingRecruiting | 180 est. | 29 Jan 2029 |
| BrAAVeA Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1NCT06844214SAR446268 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 32 est. | 28 Feb 2029 |
| STARSCAPE-1An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseaseNCT07184931Duvakitug | Phase 3 | Locked · track to reveal | OngoingRecruiting | 980 est. | 14 May 2029 |
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticaNCT07286214Sarilumab | Phase 4 | Locked · track to reveal | OngoingRecruiting | 300 est. | 4 Jun 2029 |